Praziquantel
Based on 2 publication(s) in Google Scholar
Praziquantel is a broadly effective trematocide and cestocide, the initial effect of praziquantel on the schistosome may be an interaction of the drug with lipid constituents of the tegumental membrane. Praziquantel is used for the research of schistosomiasis.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.65%
- CAS No.: 55268-74-1
- 화학식: C19H24N2O2
- 분자량:312.41
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Antiparasitic Compound library
HY-L082
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Animal Drug Library
HY-L218
-
Cardiotoxic Compound Library
HY-L225
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
Publications Citing Use of MedChemExpress (MCE) Praziquantel
MoreAll Parasite Isoforms
MoreAll Antibiotic Isoforms
More
Biological Activity
|
Schistosome |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HaCaT | CC50 |
>200 μM
Compound: PQZ
|
Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 33236902] |
| HepG2 | CC50 |
101.05 μM
Compound: PZQ
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 34536671] |
| HepG2 | CC50 |
142.8 μM
Compound: PZQ
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 34536671] |
| L6 | IC50 |
>96 μM
Compound: Praziquantel
|
Cytotoxicity against rat L6 cells incubated for 690 hrs by Alamar blue assay
Cytotoxicity against rat L6 cells incubated for 690 hrs by Alamar blue assay
|
[PMID: 23013253] |
| Sf21 | IC50 |
153.3 μM
Compound: Praziquantel
|
Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
|
[PMID: 21965623] |
| Sf21 | IC50 |
96.8 μM
Compound: Praziquantel
|
Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
|
[PMID: 21965623] |
| SH-SY5Y | CC50 |
>200 μM
Compound: PQZ
|
Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 33236902] |
Praziquantel (0.1-10 μM) enhances the tension produced by the musculature of male Schistosomajaponicum in a dose-dependent manner[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 55268-74-1
-
Appearance Solid
-
분자량 312.41
-
화학식 C19H24N2O2
-
Color White to off-white
-
SMILES
O=C1CN(C(C2CCCCC2)=O)CC3N1CCC4=C3C=CC=C4
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
-
Acta Trop
Involvement of SIRT1 in amelioration of schistosomiasis-induced hepatic fibrosis by genistein. [Abstract]2021 Aug:220:105961. PMID: 34010594
용액&용해도
DMSO : 50 mg/mL (160.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.00 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.00 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 12.5 mg/mL (40.01 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C
Add each solvent one by one: 15% Cremophor EL 85% Saline
Solubility: 30 mg/mL (96.03 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2009 mL | 16.0046 mL | 32.0092 mL | 80.0230 mL |
| 5 mM | 0.6402 mL | 3.2009 mL | 6.4018 mL | 16.0046 mL | |
| 10 mM | 0.3201 mL | 1.6005 mL | 3.2009 mL | 8.0023 mL | |
| 15 mM | 0.2134 mL | 1.0670 mL | 2.1339 mL | 5.3349 mL | |
| 20 mM | 0.1600 mL | 0.8002 mL | 1.6005 mL | 4.0012 mL | |
| 25 mM | 0.1280 mL | 0.6402 mL | 1.2804 mL | 3.2009 mL | |
| 30 mM | 0.1067 mL | 0.5335 mL | 1.0670 mL | 2.6674 mL | |
| 40 mM | 0.0800 mL | 0.4001 mL | 0.8002 mL | 2.0006 mL | |
| 50 mM | 0.0640 mL | 0.3201 mL | 0.6402 mL | 1.6005 mL | |
| 60 mM | 0.0533 mL | 0.2667 mL | 0.5335 mL | 1.3337 mL | |
| 80 mM | 0.0400 mL | 0.2001 mL | 0.4001 mL | 1.0003 mL | |
| 100 mM | 0.0320 mL | 0.1600 mL | 0.3201 mL | 0.8002 mL |
Praziquantel Related Classifications
HY-B0244 Related Classifications
Powered by Bioz